Posted on 02/08/2022 7:36:20 PM PST by SeekAndFind
Novavax Inc has delivered just a small fraction of the 2 billion COVID-19 shots it plans to send around the world in 2022 and has delayed first-quarter shipments in Europe and lower income countries such as the Philippines, public officials involved in their government's vaccine rollouts told Reuters.
Novavax said it has completed delivery of around 10 million vaccine doses to Indonesia and that shipments of several million shots arrived in Australia and New Zealand on Monday. The company declined to comment on the exact number of deliveries it has made but said it is moving as quickly as possible to ship its contracted supplies for this quarter.
Some shipments have been held up by regulatory processes and are waiting in a distribution warehouse to go to healthcare providers, Novavax spokesperson Amy Speak said.
Novavax shares fell nearly 10% in early trading.
Gaithersburg, Maryland-based Novavax, which had never launched a product, had ambitions to provide a vaccine for the world, promising to deliver its shots by mid-2021.
When the tiny company missed 2021 targets, buyers turned to rivals including Pfizer Inc/BioNTech SE, Moderna Inc, and Chinese drugmakers.
Shipments to the European Union, Indonesia and the Philippines were held back by a late regulatory approval from the World Health Organization (WHO), export limitations of its production partner the Serum Institute of India, and delayed approval of individual vaccine batches by European regulators, who must vet the shots before they can be distributed, according to officials in those regions.
The delivery delays have left at least one country reconsidering its Novavax order.
The company has yet to deliver vaccine on its largest contract for 1.1 billion doses to COVAX - a global vaccine distribution program for poorer countries - which would make Novavax its third largest supplier,
(Excerpt) Read more at news.yahoo.com ...
Too bad it was a non-mRNA vaccine and the safest of the lot. But it was made against the original spike protein from 2019. Wonder if it would still be effective.
Yeah, but we got crack pipes coming.
Nova VAX is the Solyndra of the pharmaceutical industry
Aside from the Reuters hit piece, Novavax offers a traditional protein-based vax with greater efficacy and fewer side effects than the mRNA jabs.
Do your own DD, lots of great info out there.
But they are shooting at a moving target. Inevitably the newest vaccines will only be effective against yesterday’s version of the virus - just as the current Pfizer and Moderna products continue to target an extinct variant.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.